Lilly’s eczema drug shows durable long-term response in late-stage study

March 27 (Reuters) – Eli Lilly said on Friday that its eczema drug showed durable results in a ​late-stage post-marketing study, such as  relief ‌from persistent  itch for up to four years in patients with the skin condition.

Here are more details:

(Reporting by Sneha S K in Bengaluru; Editing by ​Diti Pujara)